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Abstract
Erythropoietic protoporphyria (EPP) is an inherited disorder of the haem metabolic pathway
characterised by accumulation of protoporphyrin in blood, erythrocytes and tissues, and cutaneous
manifestations of photosensitivity. EPP has been reported worldwide, with prevalence between
1:75,000 and 1:200,000. It usually manifests in early infancy upon the first sun exposures. EPP is
characterised by cutaneous manifestations of acute painful photosensitivity with erythema and
oedema, sometimes with petechiae, together with stinging and burning sensations upon exposure
to sunlight, without blisters. These episodes have a variable severity depending on the exposure
duration and may result in chronic permanent lesions on exposed skin. As protoporphyrin is a
lipophilic molecule that is excreted by the liver, EPP patients are at risk of cholelithiasis with
obstructive episodes, and chronic liver disease that might evolve to rapid acute liver failure. In most
patients, EPP results from a partial deficiency of the last enzyme of the haem biosynthetic pathway,
ferrochelatase, EC 4.99.1.1/FECH (encoded by the FECH gene). EPP appears to be inherited as an
autosomal dominant disease, the clinical expression of which is modulated by the presence of the
hypomorphic FECH IVS3-48C allele trans, but recessive inheritance with two mutated FECH alleles
has also been described. In about 2% of patients, overt disease was recently shown to be caused
by gain-of-function mutations in the erythroid-specific aminolevulinic acid synthase 2 (ALAS2/ALAS,
EC 2.3.1.27) gene and named X-linked dominant protoporphyria. Diagnosis is established by finding
increased levels of protoporphyrin in plasma and red blood cells, and detection of a plasma
fluorescence peak at 634 nm. Investigations for hepatic involvement, ferrochelatase activity level,
genetic analysis (FECH mutations, presence of the hypomorphic FECH IVS3-48C allele trans and
ALAS2 mutations) and family studies are advisable. Differential diagnosis includes phototoxic drug
reactions, hydroa vacciniforme, solar urticaria, contact dermatitis, angio-oedema and, in some
cases, other types of porphyria. Management includes avoidance of exposure to light, reduction of
protoporphyrin levels and prevention of progression of possible liver disease to liver failure. As the
major risk in EPP patients is liver disease, a regular follow-up of hepatic involvement is essential.
Sequential hepatic and bone marrow transplantation should be considered as a suitable treatment
for most severe cases of EPP with hepatic involvement. EPP is a lifelong disorder whose prognosis
depends on the evolution of the hepatic disease. However, photosensitivity may have a significant
impact on quality of life of EPP patients.
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Disease names and synonyms
Erythropoietic protoporphyria, Protoporphyria, Haem
synthetase deficiency, Ferrochelatase deficiency, X-linked
dominant protoporphyria (XLDPP), Erythrohepatic pro-
toporphyria (no longer used).
Definition
Erythropoietic protoporphyria (EPP) is a painful photo-
dermatosis without blisters caused by inborn errors of the
haem biosynthetic pathway due, in the majority of
patients, to a deficient activity of the enzyme ferroche-
latase (ferrohaemprotolyase, haem synthetase, ferro-
haem-protolyase, EC4.99.1.1, FECH (EPP), (MIM
177000) or caused, in about 2% of patients, by a gain of
activity of the erythroid specific aminolevulinic acid syn-
thase 2 (ALAS; EC 2.3.1.27). The latter results in a new
protoporphyria named X-linked dominant protoporphy-
ria (XLDPP), (MIM 300752) [1-3].
ALAS is the first enzyme of the haem synthetic pathway,
which is synthesised by two different genes: ALAS1 in the
liver and other tissues located on chromosome 3, and
ALAS2 in the erythroid tissue located on chromosome X.
The role of ALAS is to combine glycine and succinyl-coen-
zyme A to form delta aminolevulinic acid (ALA), the first
substrate of the pathway in the mitochondrial matrix.
FECH is the last of the eight enzymes acting sequentially
in the haem biosynthetic pathway and is encoded by
FECH gene on chromosome 18. The role of FECH is to cat-
alyse the insertion of iron into protoporphyrin ring to
generate the final product, haem (Fig 1).
Porphyrias may manifest in two clinical types: cutaneous
photosensitivity (cutaneous porphyrias) or acute neuro-
visceral symptoms (acute porphyrias). EPP belongs to the
group of cutaneous porphyrias. In EPP, the enzyme defi-
ciency causes accumulation of protoporphyrin in various
tissues (skin, liver) and blood (erythrocytes and plasma).
Skin protoporphyrin accumulation results in acute epi-
sodes of painful photosensitivity without blisters, which
is the characteristic clinical manifestation of the disease.
The first comprehensive description of the disease was
published by Magnus et al. in 1961 [1].
Epidemiology
EPP has been described in patients worldwide. There are
prevalence studies in different populations, with prevalence
figures ranging between 1:75,000 (The Netherlands) and
1:200,000 (Wales) [4,5]. It seems that males and females are
equally affected, as suggested by Holme et al. [6].
Clinical description
Skin symptoms: photosensitivity
EPP manifests clinically by skin symptoms of immediate
painful photosensitivity [2,7]. This manifestation starts
usually in early infancy or childhood, upon the first sun
exposures. Skin stinging, prickling and burning on
exposed areas are the initial symptoms experienced by the
patient during or shortly after sun exposure. These symp-
toms may have a variable duration, depending on the
intensity and duration of sun exposure. If the exposure
has been long enough, erythema and oedema may
appear, together with petechiae in some cases. Areas
affected are the face and dorsa of the hands, but photosen-
sitivity reactions can also appear on any exposed skin area.
Reactions may persist for hours up to several days. The
appearance of vesicles or bullous lesions characteristic of
other forms of cutaneous porphyria is unusual but may
occur (Fig. 2, 3). Nail lesions (photoonycholysis and
transversal leuconycholysis) are possible associated man-
ifestations.
Late-onset cases have been reported but are exceptional
and related to haematologic malignancies, although cases
without this association have been described [8-10].
Repeated photosensitivity episodes result in altered skin
appearance with permanent changes, such as skin thick-
ening with a waxy or leathery appearance, and areas of
The haem biosynthesis pathway Figure 1
The haem biosynthesis pathway.
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hyperkeratosis. These lesions are usually located on the
dorsa of the hands and face, as these are skin areas usually
exposed (Fig. 4). The lips show linear furrows and pseudo-
rhagades that arte also characteristic. In contrast to other
forms of cutaneous porphyria, lesions of milia, hypertri-
chosis or hyperpigmentation do not appear. This last cuta-
neous sign may only appear in patients with severe
hepatic involvement presenting with cholestasis, itching
and jaundice [2].
Seasonal palmar keratoderma has been reported in some
EPP patients and in addition this may indicate autosomal
recessive inheritance of the disease [11].
Liver involvement
In EPP, the degree of severity of the hepatic manifestations
is variable. Hepatic disease in EPP may include: cholelith-
iasis with possible obstructive episodes and chronic liver
disease evolving to rapid acute hepatic failure [12,13].
The incidence of cholelithiasis is frequent in EPP (about
20% of patients). Gallstones with high protoporphyrin
content are generated due to the accumulation of insolu-
ble protoporphyrin and increased biliary protoporphyrin
concentration [7].
Liver disease develops in association with EPP in 1-4% of
cases [5,6], with usual features of visceral enlargement
and portal hypertension. Liver disease in protoporphyria
is related to the excess protoporphyrin cleared by the
entero-hepatic circulation leading to paracrystalin pro-
toporphyrin deposition in hepatocytes and precipitation
in the biliary canaliculiy. The percentage of patients who
will develop liver disease is not established, nor specific
factors that may influence its development. It is not possi-
ble to predict whether or not acute hepatic failure will
occur. Studies have revealed that an increase in copropor-
phyrin urinary excretion, together with a change in isomer
predominance from isomer III to isomer I, and increasing
levels of protoporphyrinaemia may precede this compli-
cation [14].
Progression of protoporphyric hepatic deterioration leads
to splenomegaly, splenic sequestration of erythrocytes
with haemolysis (which increases erythropoiesis) and
protoporphyrin generation ending in fulminant hepatic
failure [13-15].
Patients who have FECH mutations on both alleles or a
gain of function mutation of ALAS2 [3] have an increased
risk of liver disease though together they account for only
a small proportion of those with liver disease.
Acute photosensitivity reaction in EPP Figure 2
Acute photosensitivity reaction in EPP.
Acute photosensitivity reaction in EPP Figure 3
Acute photosensitivity reaction in EPP.
Chronic skin lesions of EPP Figure 4
Chronic skin lesions of EPP.Orphanet Journal of Rare Diseases 2009, 4:19 http://www.ojrd.com/content/4/1/19
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An unsual neurological syndrome has been described
with progressive polyneuropathy, swallowing difficulties
and respiratory distress in several patients with end-stage
liver disease due to protoprophyria [16]. Oral mucosa or
eye lesions in EPP patents have recently been reported for
the first time by Tsuboi H et al. [17].
Pathological features of EPP
Cutaneous lesions result from the presence of protopor-
phyrin in erythrocytes and plasma in skin vasculature.
Histologically, hyaline PAS-positive perivascular material
deposits can be found together with extensive presence of
fine fibrillar material, and reduplication of blood vessel
walls and epidermal basal lamina. Although less promi-
nent, these findings appear also in other cutaneous por-
phyrias (Fig 5).
Deposition of protoporphyrin in hepatocytes and in
thrombi within the biliary canaliculi can be observed in
the hepatic tissue. Characteristic pigment depositions are
produced and under polarised light birefringent crystal-
line structures appear with the characteristic Maltese cross
shape. Canaliculi may be dilatated and amorphous
deposits within the lumen may be present [7].
Biochemical and haematological alterations
Partial deficiency of FECH produces accumulation of free
protoporphyrin IX. It can be detected in circulating red
blood cells, in reticulocytes and in bone marrow erythrob-
lasts. Red blood cells are therefore fluorescent under
Wood's light. Protoporphyrin may also be detected in
patients' plasma, that may also be fluorescent. Protopor-
phyrin is often excreted in stool and can be detected, but
not in all patients. Urine is usually normal, except in cases
with cholestasis and protoporphyrin hepatopathy. In this
situation, an excess of urinary coproporphyrin isomer I
can be demonstrated. FECH deficiency can be detected in
different tissues with levels usually under 50% of normal
(between 10 - 30%) to induce clinical manifestations [6].
Recently, families have been described in which EPP is
inherited in an X-linked dominant pattern [3]. Patients
with this disorder have normal FECH activities but higher
erythrocyte total protoporphyrin concentrations than
other types of EPP of which around 40% is zinc-protopor-
phyrin. This high proportion of zinc-protoporphyrin sug-
gests that protoporphyrin accumulates because supply of
both its metal substrates, Fe2+ and Zn2+, becomes rate-lim-
iting. Additionally, the increase in erythrocyte zinc-pro-
toporphyrin in combination with a marked increase in
free protoporphyrin appears to be a distinguishing feature
of this form of EPP [18,19].
Microcytic anaemia occurs in 20% to 60% of patients.
Erythropoiesis was impaired in most patients with domi-
nant EPP from UK and France [18,19]. All had a down-
ward shift in haemoglobin (Hb), women were slightly
more anaemic than men. Iron stores, assessed by serum
ferritin (sFn), were decreased by two-thirds, but normal
serum soluble transferrin receptor-1 and iron concentra-
tions suggested that erythropoiesis was not limited by
iron supply. FECH deficiency in EPP appears to lead to a
steady state in which decreased erythropoiesis is matched
by reduced iron absorption and supply. This response
may in part be mediated by protoporphyrin [18].
Aetiopathogenesis
EPP clinical manifestations are consequence of protopor-
phyrin accumulation in various tissues. The protoporphy-
rin molecule absorbs light radiation in a range of
wavelengths from 320 to 595 nm. The absorption of these
wavelengths increases the energy content of the protopor-
phyrin molecule (inducing a triplet state) and enables the
excess energy to be transferred to oxygen, resulting in a
reactive oxygen species that may interact with many bio-
logical molecules, such as proteins, lipids and DNA (pho-
todynamic reactions) [20].
As protoporhyrin is a hydrophobic molecule, it tends to
accumulate in cellular membranes. Upon irradiation with
the specific wavelengths mentioned above, a photody-
namic reaction takes place in tissues where protoporphy-
rin is present (skin, red blood cells in skin blood vessels)
and cellular membranes are damaged because of mem-
brane lipids peroxidation. Oxygen species generation may
also injure tissues by complement activation and mast cell
degranulation phenomena that explain the vasodilatation
and oedema components of the skin photosensitivity
reactions in EPP patients.
Cutaneous histological features of EPP with PAS positive  material deposition around papilar blood-vessels and dermo- epidermal junction Figure 5
Cutaneous histological features of EPP with PAS pos-
itive material deposition around papilar blood-ves-
sels and dermo-epidermal junction.Orphanet Journal of Rare Diseases 2009, 4:19 http://www.ojrd.com/content/4/1/19
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Histological examination of the skin upon sun exposure
in EPP patients reveals the presence of inflammatory reac-
tion arround dermal capillaries, with inflammatory infil-
tration. Subsequently, a repair reaction ensues with
collagen synthesis. This process is produced repeatedly
and manifests histologically by a deposition of PAS-posi-
tive material around skin blood vessels, which, on the
other hand, show reduplication of capillary basal mem-
branes [21].
Protoporphyrin is highly toxic, independently of the pho-
tosensitized reactions. Possible mechanisms underlying
this hepatic toxicity have been described, but none of
these hypotheses have been confirmed. The basic conse-
quence is that the biliary system is exposed to high con-
centrations of protoporphyrin that saturate the excretion
capacity. Deposits of protoporphyrin are formed and fur-
ther reduce excretion capacity. Hepatic inflammation may
appear with disordered tissue regeneration, hepatic fibro-
sis and cirrhosis associated with biliary disease [7,21,22].
Genetics
With only rare exceptions, EPP is an inherited disorder.
Even after the identification of mutations in the FECH
gene in EPP, the precise pattern of inheritance remained
uncertain. The difference in FECH activity between clini-
cally overt and latent individuals could not readily be
explained by the prevailing view that inheritance was
autosomal dominant with low clinical penetrance but was
consistent with a three allele system. Recent genetic stud-
ies revealed different patterns of inheritance in EPP
[23,24].
In most patients with EPP, a FECH mutation that mark-
edly decreases or abolishes enzyme activity can be identi-
fied on only one allele [23,25-30]. The discovery that
clinical expression of this type of EPP normally required a
hypomorphic FECH IVS3-48C allele trans to the mutation
was demonstrated in France [26,31] and was independ-
ently confirmed by studies from Japan, North America,
Sweden, Israel, South Africa, the United Kingdom [28,30-
34].
The pattern of inheritance of photosensitivity has been
well documented by Went and Klasen [4] who investi-
gated 91 families from the Netherlands, most of whom
were likely to have had this type of EPP. About half the
cases were sporadic. When a family contained more than
one patient, affected siblings were more common than
parent to child transmission. The number of families with
patients in more than one generation increases with the
population prevalence, occurring in 15% of French and
51% of Japanese families. In contrast, EPP caused by
FECH deficiency has not been reported in black South
African families [26,33].
FECH mutations on both alleles are an uncommon cause
of EPP. To date, twenty-one symptomatic patients from
17 families have been reported. In the UK and France, this
type of EPP accounts for about 4% of EPP families.
Reported FECH activities, either measured in lymphocytes
or estimated from in vitro expression studies, are within
the median range of 9%. Molecular analyses show that
most of the patients are compound heterozygotes. In
marked contrast to the type of EPP described above, mis-
sense mutations make up 85% of the total and null muta-
tions are unusual [28,30-34].
The pattern of inheritance of photosensitivity in these
families is characteristic of an autosomal recessive disor-
der. There is an increased incidence of consanguinity, only
siblings are affected and both parents are clinically nor-
mal. This last feature may in part be explained by the
chance absence of a hypomorphic allele trans to the muta-
tion [35,36],
Acquired somatic FECH mutations have been identified
in a small number of patients in whom EPP has developed
after the age of 40 years in association with myelodyspla-
sia or myeloproliferative disorder [10,37].
Patients in which EPP is inherited in an X-linked domi-
nant pattern have normal FECH activities but higher
erythrocyte total protoporphyrin concentrations than
other types of EPP of which around 40% is zinc-protopor-
phyrin. Two frameshift mutations have been identified in
8 families that lead to predicted disruption or deletion of
the 19-20 C-terminal amino-acids of ALAS2. Prokaryotic
expression studies show that both mutations markedly
increase ALAS2 activity. Thus the C-terminal region of
ALAS2 appears to inhibit enzyme activity; its removal by
mutation leads to gain of function whereas all other pre-
viously described mutations in ALAS2  decrease activity
and cause hereditary sideroblastic anaemia.
Despite advances in techniques for mutation detection
and the discovery of gain in function mutations of ALAS2
as a cause of EPP, in about 5% of EPP families no muta-
tions in neither FECH or ALAS2 genes have been identi-
fied. Disease in these families is strongly associated with
inheritance of the hypomorphic FECH  IVS3-48C allele
and decreased FECH activity which suggests that most
may have mutations in regions of the FECH gene that are
not included in current strategies for mutation detection.
Genotype/phenotype correlations
The cutaneous features of EPP, though varying in severity
are remarkably uniform. No correlation between indices
of severity of photosensitivity, such as age of onset or
duration of symptoms, and genotype have yet been
reported apart from the suggestion that the relatively com-Orphanet Journal of Rare Diseases 2009, 4:19 http://www.ojrd.com/content/4/1/19
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mon missense mutation, P334L, may cause only mild dis-
ease Apart from this instance, no correlation between
erythrocyte protoporphyrin concentration and type of
FECH mutation has been reported. Seasonal palmar kera-
toderma has to date been reported only in patients who
are compound heterozygotes or homozygotes for FECH
mutations [19,38].
A mainly literature-based study of 112 patients with a sin-
gle FECH mutation, of whom 18 had severe liver disease,
found that all patients with liver disease had a 'null' muta-
tion (splicing defect, nonsense or frameshift) while none
of the 20 patients with a missense mutation had liver dis-
ease; this difference was statistically significant [39].
Under-representation of missense mutations was also
noted in a group of 15 patients with liver disease, all stud-
ied in the same laboratory, but comparison with a group
without liver disease did not reach statistical significance
[4,35]. Together these studies suggest that missense muta-
tions that preserve significant amounts of residual activity
may carry a lower risk of liver disease than 'null' muta-
tions, a group that includes those misssense mutations
that abolish FECH activity. However, 'null' mutations
associated with liver disease are found more frequently in
patients without liver disease; an observation that indi-
cates the probable importance of genetic factors outside
the FECH locus and acquired factors in the pathogenesis
of protoporphyric liver disease [40].
Diagnosis
Photosensitivity, with the characteristic painful inflam-
matory reaction without blistering, is the clinical basis for
diagnosis of EPP. Screening by fluorescence microscopy
for the presence of fluorescent erythrocytes - fluorocytes -
in a fresh unstained blood smear may be the first step in
confirmation of the EPP diagnosis. This step should be
followed by the detection of a plasmatic fluorescence peak
at 634 nm (630 - 635) and the demonstration of high free
protoporphyrin levels in plasma and erythrocytes or a
higher content and percentage of zinc-protoporphyrin in
XLDPP patients. Presence of increased protoporphyrin in
the stools may also be a useful diagnostic finding. These
data confirm the diagnosis of EPP (Fig 6). In addition, the
levels of FECH activity in selected tissues may be deter-
mined.
Hepatic function should be tested and abdominal ultra-
sonographic examination should be performed to detect
cholelithiasis.
Screening for either FECH  gene mutations and for the
presence of the IVS3-48C hypomorphic FECH allele or
ALAS2 gain of function mutations, together with studies
of family members, may also be proposed. These data will
be useful for genetic counselling [7].
Differential diagnosis
Clinically, EPP should be differentiated from phototoxic
drug reactions, hydroa vacciniforme, solar urticaria. Con-
tact dermatitis and angioedema or even other types of
curaneous porphyria could also be considered. Chronic
lesions should be differentiated from lipoid proteinosis
[7].
Biochemically, excess protoporphyrin should be present
in the form of free protoporphyrin. Elevated zinc
chelated-protoporphyrin levels could indicate iron defi-
ciency or lead poisoning but also now the X-linked EPP
due to ALAS2 gain of function mutations. Elevated levels
EPP diagnosis Figure 6
EPP diagnosis.
Painful photosensitivity on sun-exposed skin 
with erythema, œdema, petechiae + 
stinging, prickling and burning 
without blisters 
Plasma fluoresence peak at 
                                    634 nm  testing  
If positive 
Plasma / erythrocytic 
free protoporphyrin concentration + 
Faecal protoprophyrin concentration  
If  increased
                 Diagnosis: Erythropoietic Protoporphyria
Or X Linked Dominant Protoporphyria 
(If Zn-protoporphyrin % increased +++) 
          (Determination of FECH activity level) 
                                   if available 
Liver examination 
Liver function tests,viral 
hepatitis serology, 
hemochromatosis test, 
serum markers for hepatic 
fibrosis, Liver imageing 
   Urinary coproporphyrin 
FECH mutation + IVS3-48C 
allele determination 
ALAS2 mutations 
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of zinc-protoprophyrin may be detected in homozygotes
with other inherited forms of porphyria [7,41].
Genetic counselling
In the classic EPP with FECH mutation on one allele and
hypomorphic FECH IVS3-48C allele in trans position, the
probability for the offspring of an EPP patient to present
the disease is less than 1:40 (less than 2.5%). Hypomor-
phic FECH allele in the general population (Caucasians)
has a prevalence of around 10% [26,40]. Screening for the
presence of the FECH IVS3-48C hypomorphic allele in the
EPP patient's partner allows more accurate estimation of
this probability.
During pregnancy, EPP is usually not a problem neither
for the mother nor for the baby. With the exception of one
recently published case, the reported cases of pregnancy in
patients with EPP have revealed that symptoms of photo-
sensitivity improve during pregnancy, with reduction of
erythrocyte protoprophyrin levels [42].
Management
Management of photosensitivity
Management of photosensitivity is an essential therapeu-
tic measure. Avoidance of sun exposure, even through
window glass (e.g. car driving), is the most practical way
of preventing photosensitivity reactions in EPP patients.
The use of adequate clothing (hats, glasses, gloves) and
sunscreens is also advisable. Due to the fact that protec-
tion should cover both long-wave radiation plus visible
light, physical sunscreens are more effective.
Management of photosensitivity reactions includes the
use of: wet (cold) water compresses applied to the affected
areas. Topical corticosteroids may be prescribed but are
usually ineffective. Oral treatment, if required, may
include non-steroidal anti-inflammatory drugs or oral
corticosteroids.
Betacarotene has been used extensively, with the aim of
improving light tolerance in EPP patients. Some benefit
from its use has been experienced by patients. The follow-
ing doses of betacarotene are recommended: up to 90-120
mg/day in children and up to 180-300 mg/day in adults.
Recent studies, however, have suggested inverse associa-
tions between carotenoids and lung cancer mainly in
smokers [43,44].
Other treatment approaches include the administration of
Vitamin C and E, and cysteine (500 mg/twice daily),
orally. Antihistamines may also be used as they may limit
the phototoxic reaction.
Except for betacarotene, there is a lack of firm evidence
proving the effectiveness of all these treatment approaches
[45]. The duration of treatments directed to improve pho-
tosensitivity is related to the ratio risk/benefit obtained by
patients individually. UVB/NBUVB phototherapy or
PUVA may be used in order to induce tanning and
improve the sunlight tolerance. The duration of the treat-
ment is limited by the guidelines of phototherapy and
depends also on the patient benefit obtained in reduction
of photosensitivity [46].
Afamelanotide (an alpha-melanocyte-stimulating hor-
mone analogue that induces epidermal melanin forma-
tion) has recently been shown to have beneficial effects in
patients with EPP [47].
EPP patients may present photosensivity reactions during
surgical procedures due to exposure to the theater lighting
or other surgical light conducting devices in laparoscopy,
endoscopy or dental procedures. In these cases, the appli-
cation of yellow filters blocking the radiation under 460
nm offers the best protection in keeping with a level of
normal acceptable visibility [48,49].
Reduction of protoporphyrin levels
Regarding the reduction of excess protoporhyrn in
patients with EPP, two approaches can be considered:
a) Reduction of erythropoiesis. This may be achieved by
exchange transfusion or hypertransfusion. It is not clear if
haematin may temporarily supress erythropoiesis by
modifying the activity of the rate-limiting first enzyme of
the haem synthetic pathway, ALA synthase. However, this
approach cannot be considered as a long-term treatment
of the disease [50-52].
b) Cholestyramine (a bile sequestering agent) may be
used to increase the elimination of the excess protopor-
phyrin through the biliary system. It binds the excess pro-
toprophrin, enhancing its faecal elimination, reducing its
plasma and red blood cell concentration, and preventing
the protoporphyric hepatopathy. The suggested dose of
cholestyramine is 4-16 g daily. Other similar drugs have
been considered, such as chenodeoxycholic acid and urso-
deoxycholic acid [53-55].
However these bile sequestering agents might have no or
even adverse effect in a mouse model of EPP with progres-
sive liver disease and should be therefore used with cau-
tion (JC Deybach and H Puy, personal communication).
Management of microcytic anaemia
Patients studied had a mild microcytic anaemia and
thrombocytopenia, as shown by the downward shift of
hematologic parameters, which positively correlated with
the amount of erythrocyte PPIX. Interestingly, erythropoi-
esis did not seem to be limited by iron supply in patients,Orphanet Journal of Rare Diseases 2009, 4:19 http://www.ojrd.com/content/4/1/19
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since serum iron and soluble transferrin (Tf) receptor
(sTfR) were normal. Therefore oral iron supply is usually
found ineffective in trying to correct the usual mild anae-
mia in EPP patients and is therefore not recommended.
However intravenous iron supply or even blood transfu-
sion should be considered in EPP with a more pro-
nounced anaemia [7].
Management of liver disease
Liver transplantation is the treatment for end-stage liver
disease. It was used for the first time in an EPP patient in
1980 [55]. Progressive liver disease in EPP patients should
be considered a medical emergency and, therefore, liver
transplantation has ben indicated in patiens with EPP.
It is evident that liver transplantation does not alter the
consequences of FECH deficiency and overproduction of
proporhyrin. Therefore, the EPP patients continue to
present with the typical symptoms and same risks. Bone
marrow transplantation should be considered and, in fact,
the ideal treatment should be sequential liver and bone
marrow transplantation, which has already been per-
formed with success [56,57].
As the experience with liver and bone marrow transplan-
tations in EPP patients increases, rationale for patient
selection, indication for transplantation and timing either
for bone marrow, liver or sequential transplantations can
be established. Knowledge concerning tolerance of the
immunosuppressive therapy and long-term complica-
tions in EPP patients also needs to be gained. A proposal
of guidelines to identify liver disease in EPP patients has
been published by Anstey and Rift very recently [58]. Spe-
cial attention should be devoted to EPP patients bearing
FECH  null mutations with recessive inherited disease,
those belonging to families with more than one member
with manifested disease or those with X linked protopor-
phyria.
Liver biopsy should be indicated in patients with null
mutations or recessive inherited disease, patients from
families with previous cases of EPP liver disease, and in
individuals with EPP plus other risk factors for liver dis-
ease (such as hepatitis, haemochromatosis, alcoholic or
non-alcoholic fatty liver disease, abnormal liver function
tests). Special attention should also be given to patients
with sudden worsening of photosensitivity, rising blood
protoporphyrin levels, increasing urinary coproporphy-
rinuria isomer I and decreasing faecal protoprophyrin.
EPP patients should be monitored through a periodic
non-invasive liver testing protocol that includes liver
function tests, viral hepatitis serology, haemochromatosis
tests and analysis for serum markers of hepatic fibrosis.
Liver scanning for detection of gallstones, and computed
tomography (CT) and magnetic resonance imaging (MRI)
liver studies should also be included.
EPP patients should be vaccinated against hepatitis. They
should avoid alcohol intake.
Prognosis
EPP is a lifelong disease whose prognosis depends on the
evolution of the hepatic disease that may lead to poten-
tially fatal liver failure. Regarding life quality aspects, only
one study has addressed this question in porphyric
patients and, specifically, in EPP patients. It has been con-
cluded that photosensitivity may significantly modify the
life style of EPP patients, with a marked impact on the
quality of life and with scores that appear higher in EPP
patients as compared to those for other skin diseases con-
sidered as severe [6].
Abbreviations
EPP: erythropoietic protoporphyria; FECH: ferrohaem-
protolyase; ALAS: aminolevulinic acid synthase; XLDPP:
X-linked dominant protoporphyria; ALA: aminolevulinic
acid; Hb: haemoglobin; SFn: serum ferritin; Tf: transferrin;
STfR: soluble transferrin receptor; CT: computing tomog-
raphy; MRI: magnetic resonance imaging
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
ML wrote the first draft of the manuscript; all authors
revised the manuscript and approved the final version.
Acknowledgements
We thank Pr Laurent Gouya (Paris, France) Pr George Elder and Pr Mike 
Badminton (Cardiff, UK) for helpful discussion and contribution to the man-
uscript.
References
1. Magnus IA, Jarret A, Prankerd TAJ, Rimington C: Erythropoietic
protoporphyria: a new porphyria syndrome with solar urti-
caria due to protoporphyrinæmia.  Lancet 1961, 278:574-581.
2. Cox TM: Protoporpnhyria.  In The Porphyrin Handbook. Medical
Aspects of Poprhyrias, Chap. 90 Volume 14. Edited by: Kadish KM, Smith
KM, Guilard R. Academic Press. San Diego; 2003:121-149. 
3. Whatley SD, Ducamp S, Gouya L, Grandchamp B, Beaumont C, Bad-
minton MN, Elder GH, Holme SA, Anstey AV, Parker M, Corrigall AV,
Meissner PN, Hift RJ, Marsden JT, Ma Y, Mieli-Vergani G, Deybach JC,
Puy H: C-terminal deletions in the ALAS2 gene lead to gain
of function and cause X-linked dominant protoporphyria
without anemia or iron overload.  Am J Hum Genet 2008,
83:408-14.
4. Went L, Klasen EC: Genetic aspects of erythropoietic pro-
toporphyria.  Ann Hum Genet 1984, 48:105-117.
5. Elder GH, Smith SG, Smyth SJ: Laboratory investigation of the
porphyrias.  Ann Clin Biochem 1990, 27:395-412.
6. Holme SA, Anstey AV, Finlay AY, Elder GH, Badminton MN: Eryth-
ropoietic protoporphyria in the U.K.: clinical features and
effect on quality of life.  Br J Dermatol 2006, 155:574-581.
7. Thunell S, Harper P, Brun A: Porphyrins, porphyrin metabolism
and porphyrias. IV. Pathophysiology of erythyropoietic pro-Orphanet Journal of Rare Diseases 2009, 4:19 http://www.ojrd.com/content/4/1/19
Page 9 of 10
(page number not for citation purposes)
toporphyria--diagnosis, care and monitoring of the patient.
Scand J Clin Lab Invest 2000, 60:581-604.
8. Bharati A, Badminton MN, Whatley SD, O'Brian DV, Bell HK: Late-
onset erythropoietic protoporphyria in association with hae-
matological malignancy.  Clin Exper Dermatol 2006, 31:668-670.
9. Berroeta L, Man I, Goudie DR, Whatley SD, Elder GH, Ibbotson SH:
Late presentation of erythropoietic protoporphyria: case
report and genetic analysis of familiy members.  Br J Dermatol
2007, 157:1030-1031.
10. Goodwin RG, Kell WJ, Laidler P, Long CC, Whatley SD, McKinley M,
Badminton MN, Burnett AK, Williams GT, Elder GH: Photosensi-
tivity and acute liver injury in myeloproliferative disorder
secondary to late-onset protoporphyria caused by deletion
of a ferrochelatase gene in hematopoietic cells.  Blood 2006,
107:60-2.
11. Holme SA, Whatley SD, Roberts AG, Anstey AV, Elder GH, Ead RD,
Stewart MF, Farr PM, Lewis HM, Davies N, White MI, Ackroyd RS,
Badminton MN: Seasonal palmar keratoderma in erythropoi-
etic protoporphyria indicates autosomal recessive inherit-
ance.  J Invest Dermatol 2009, 129:599-605.
12. Meerman L: Erythropietic protoporphyria: an overview with
emphasis on the liver.  Scan J Gastroenterol 2000, 35(Suppl
232):79-85.
13. Bruguera M, Herrero C: [Liver disease in erythropoietic pro-
toporphyria].  Gastroenterol Hepatol 2005, 28:632-636.
14. Todd DJ: Erythropoietic protoporphyria.  Br J Dermtol 1994,
131:751-756.
15. Bonkovsky HL, Schned AR: Fatal liver failure in protoporphyria.
Synergism between ethanol excess and the genetic defect.
Gastroenterology 1986, 90:191-201.
16. Muley SA, Midani HA, Rank JM, Carithrs R, Parry GJ: Neuropathy in
erythropoietic protoprophyrias.  Neurology 1998, 51:262-265.
17. Tsuboi H, Yonemoto K, Katsuoka K: Erythropoietic protopor-
phyria with eye complications.  J Dermatol 2007, 34:790-794.
18. Delaby C, Lyoumi S, Ducamp S, Martin-Schmitt C, Gouya L, Deybach
JC, Beaumont C, Puy H: Excessive erythrocyte ppix influences
the hematologic status and iron metabolism in patients with
dominant erythropoietic protoporphyria.  Cell Mol Biol (Noisy-le-
grand) 2009, 55(1):45-52.
19. Holme SA, Worwood M, Anstey AV, Elder GH, Badminton MN:
Erythropoiesis and iron metabolism in dominant erythropoi-
etic protoporphyria.  Blood 2007, 110:4108-4110.
20. Lim H: Pathophysiology of cutaneous lesions in porphyrias.
Semin Hematol 1989, 26:114-119.
21. Poh-Fitzpatrick MB: Pathogenesis and treatment of photocuta-
neous manifestations of the porphyrias.  Semin Liver Dis 1982,
2:164-176.
22. Knobler E, Poh-Fitzpatrick MB, Kravetz D, Vincent WR, Muller-Eber-
hard U, Vincent SH: Interaction of hemopexin, albumin and
liver fatty acid-binding protein with protoporphyrin.  Hepatol-
ogy 1989, 10:995-997.
23. Rüfenacht UB, Gouya L, Schneider-Yin X, Puy H, Schäfer BW,
Aquaron R, Nordmann Y, Minder EI, Deybach JC: Systematic anal-
ysis of molecular defects in the ferrochelatase gene from
patients with erythropoietic protoporphyria.  Am J Hum Genet
1998, 62:1341-52.
24. Nordmann Y, Deybach JC: Human hereditary porphyrias.  In Bio-
synthesis of heme and chlorophylls Edited by: Dailey HA. McGraw-Hill:
New York; 1990:491-542. 
25. Aurizi C, Schneider-Yin X, Sorge F, Macrì A, Minder EI, Biolcati G:
Heterogeneity of mutations in the ferrochelatase gene in
Italian patients with erythropoietic protoporphyria.  Mol
Genet Metab 2007, 90:402-7.
26. Gouya L, Martin-Schmitt C, Robreau AM, Austerlitz F, Da Silva V,
Brun P, Simonin S, Lyoumi S, Grandchamp B, Beaumont C, Puy H,
Deybach JC: Contribution of a single-nucleotide polymor-
phism to the genetic predisposition for erythropoietic pro-
toporphyria.  Am J Hum Genet 2006, 78:2-14.
27. Herrero C, To-Figueras J, Badenas C, Méndez M, Serrano P, Enríquez-
Salamanca R, Lecha M: Clinical, biochemical, and genetic study
of 11 patients with erythropoietic protoporphyria including
one with homozygous disease.  Arch Dermatol 2007, 143:1125-9.
28. Risheg H, Chen FP, Bloomer JR: Genotype determinants of phe-
notype in North American patients with erythropoietic pro-
toporphyria.  Mol Genet Metab 2003, 80:196-206.
29. Saruwatari H, Ueki Y, Yotsumoto S, Shimada T, Fukumaru S,
Kanekura T, Kanzaki T: Genetic analysis of the ferrochelatase
gene in eight Japanese patients from seven families with
erythropoietic protoporphyria.  J Dermatol 2006, 33:603-8.
30. Wiman A, Floderus Y, Harper P: Novel mutations and pheno-
typic effect of the splice site modulator IVS3-48C in nine
Swedish families with erythropoietic protoporphyria.  J Hum
Genet 2003, 48:70-6.
31. Whatley SD, Mason NG, Khan M, Zamiri M, Badminton MN, Missaoui
WN, Dailey TA, Dailey HA, Douglas WS, Wainwright NJ, Elder GH:
Autosomal recessive erythropoietic protoporphyria in the
United Kingdom: prevalence and relationship to liver dis-
ease.  J Med Genet 2004, 41:e105.
32. Nakano H, Nakano A, Toyomaki Y, Ohashi S, Harada K, Moritsugu R,
Takeda H, Kawada A, Mitsuhashi Y, Hanada K: Novel ferroche-
latase mutations in Japanese patients with erythropoietic
protoporphyria: high frequency of the splice site modulator
IVS3-48C polymorphism in the Japanese population.  J Invest
Dermatol 2006, 126:2717-9.
33. Parker M, Corrigall AV, Hift RJ, Meissner PN: Molecular character-
isation of erythropoietic protoporphyria in South Africa.  Br
J Dermatol 2008, 159:182-191.
34. Schneider-Yin X, Mamet R, Minder EI, Schoenfeld N: Biochemical
and molecular diagnosis of erythropoietic protoporphyria in
an Ashkenazi Jewish family.  J Inherit Metab Dis 2008 in press.
35. Chen F-P, Risheg H, Liu Y, Bloomer J: Ferrochelatase gene muta-
tions in erythropoietic protoporphyria: focus on liver dis-
ease.  Cell Mol Biol 2002, 48:83-9.
36. Bloomer J, Wang Y, Singhal A, Risheg H: Molecular studies of liver
disease in erythropoietic protoporphyria.  J Clin Gastroenterol
2005, 39(supp 2):167-175.
37. Sarkany RP, Ross G, Willis F: Acquired erythropoietic protopor-
phyria as a result of myelodysplasia causing loss of chromo-
some 18.  Br J Dermatol 2006, 155:464-6.
38. Méndez M, Poblete-Gutiérrez P, Morán-Jiménez MJ, Rodriguez ME,
Garrido-Astray MC, Fontanellas A, Frank J, de Salamanca RE: A
homozygous mutation in the ferrochelatase gene underlies
erythropoietic protoporphyria associated with palmar kera-
toderma.  Br J Dermatol 2009, 160(6):1330-4. Epub 2009 Mar 9.
39. Minder EI, Gouya L, Schneider-Yin X, Deybach J-C: A genotype-
phenotype correlation between null allele mutations in the
ferrochelatase gene and liver complication in patients with
erythropoietic protoporphyria.  Cell Mol Biol 2002, 48:91-6.
40. Gouya L, Puy H, Robreau AM, Bourgeois M, Lamoril J, Da Silva V,
Grandchamp B, Deybach JC: The penetrance of dominant eryth-
ropoietic protoporphyria is modulated by expression of
wildtype FECH.  Nature Genetics 2006, 30:27-28.
41. Sarkany RPE, Breathnach SM, Seymour CA, Weismann K, Burns DA:
The cutaneous Porphyrias.  In Textbook of Dermatology Volume 3.
7th edition. Edited by: Burns T, Breathnach S, Cox N, Griffiths C.
Oxford, Blackwell Publishing; 2004:57.  20.
42. Poh-Fitzpatrick MB: Human protoporphyria: reduced cutane-
ous photosensitivity and lower erythrocyte porphyrin levels
during pregnancy.  J Am Acad Dermatol 1997, 36:40-43.
43. Gallicchio L, Boyd K, Matanoski G, Tao XG, Chen L, Lam TK, Shiels
M, Hammond E, Robinson KA, Caulfield LE, Herman JG, Guallar E,
Alberg AJ: Carotenoids and the risk of developing lung cancer:
a systematic review.  Am J Clin Nutr 2008, 88(2):372-83.
44. Al-Wadei HA, Schuller HM: Beta-Carotene promotes the devel-
opment of NNK-induced small airway-derived lung adeno-
carcinoma.  Eur J Cancer 2009, 45(7):1257-64. Epub 2009 Feb 28.
45. Corbett MF, Herxheimer A, Magnus IA, Ramsay CA, Kobza-Black A:
The long-term treatment with betacarotene in erythropoi-
etic protoporphyria: a controlled trial.  Br J Dermatol 1977,
97:655-662.
46. Warren LJ, George S: Erythropoietic protoporphyria treated
with narrow-band (TL-01) UVB phototherapy.  Australas J Der-
matol 1998, 39:179-182.
47. Harms J, Lautenschlager S, Minder CE, Minder EI: An alpha-
melanocyte-stimulating hormone analogue in erythropoi-
etic protoporphyria.  N Engl J Med 2009, 360(3):306-7.
48. Meerman L, Verwer R, Schoff MJ: Perioperative measures durin
Liver Transplantation fo Erythropoietic Protoporphyria.
Transplantation 1994, 57:155-158.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Orphanet Journal of Rare Diseases 2009, 4:19 http://www.ojrd.com/content/4/1/19
Page 10 of 10
(page number not for citation purposes)
49. Wahlin S, Harper P, Brun A: Protection from phototoxic injury
in Erythropoietic Protoporphyria.  Proceedings Porphyrins and Por-
phyrias. Rotterdam 2007:51. Abstract S07-3
50. Dobozy A, Csató M, Siklósi C, Simon N: Transfusion therapy for
erythropoietic protoporphyria.  Br J Dermatol 1983,
109:571-576.
51. Dellon ES, Szczepiorkowski ZM, Dzik WH, Graeme-Cook F, Ades A,
Bloomer JR, Cosimi AB, Chung RT: Treatment of recurrent allo-
graft dysfunction with intravenous hematin after liver trans-
plantation for erythropoietic protoporphyria.  Transplantation
2002, 73:911-9152.
52. Wahlin S, Aschan J, Björnstedt M, Broome U, Harper P: Curative
bone marrow transplantation in erythropoietic protopor-
phyria after reversal of severe cholestasis.  J Hepatol 2007,
46(1):174.
53. Frank M, Doss MO: Liver and liver cirrhosis in protoporphyria:
bile acid therapy.  Gastroenterology 1995, 33(7):399-403.
54. McCullough AJ, Barron D, Mullen KD, Petrelli M, Park MC, Mukhtar
H, Bickers DR: Fecal protoporphyrin excretion in erythropoi-
etic protoporphyria: effect of cholestyramine and bile acid
feeding.  Gastroenterology 1988, 94:177-181.
55. Wells MM, Golitz LE, Bender BJ: Erythropoietic protoporphyria
with hepatic cirrhosis.  Arch Dermatol 1980, 116:29432.
56. Metselaar HJ: Long-term results of liver transpantation for
protoporphyria.  Proceedings Porphyrins and Porphyrias. Rotterdam
2007:50. Abstract S07-2
57. Rand EBm, Bunin N, Cochran W, Ruchelli E, Olthoff KM, Bloomer JR:
Sequential liver and bone marrow transplantation for tret-
ment of erythropoietic protopor'hyria.  Pediatrics 2006,
118(6):e1896-1899.
58. Anstey AV, Hift RJ: Liver disease in erythropoietic protopor-
phyria: insights and implications for management.  Gut 2007,
56:1009-1018.